Senores Pharmaceuticals IPO - Day 3 Subscription at 19.05 Times

Senores Pharmaceuticals' initial public offering (IPO) has received exceptional investor interest over the three-day period. The IPO witnessed strong growth in demand, with subscription rates progressing from 1.94 times on day one, to 14.65 times on day two, and reaching 19.05 times by 10:44 AM on the final day.

Senores Pharmaceuticals IPO, which opened on 20th December 2024, has seen remarkable participation across categories. The Retail Investors segment has shown outstanding interest, reaching 48.04 times subscription, while Non-Institutional Investors achieved strong subscription at 36.67 times. The QIB portion stands at 0.37 times.

This robust response comes amid positive sentiment in the Indian stock market, particularly towards companies in the pharmaceutical sector with global presence.

Subscription Status of Senores Pharmaceuticals IPO:

*As of 10:44 AM

Here are the subscription details for Senores Pharmaceuticals IPO as of Day 3 (24th December 2024, 10:44 AM):

Total Applications: 17,56,226

Note:

Senores Pharmaceuticals IPO Key Highlights:

• "Shares Offered" and "Total Amount" are calculated based on the upper price of the issue price range.
• The portion of anchor investors is not included in the total shares offered.
• Overall subscription reached exceptional 19.05 times on the final day
• Retail investors showing overwhelming response at 48.04 times subscription
• Non-Institutional Investors achieved remarkable 36.67 times subscription
• Small NII segment leading with 46.88 times subscription
• Large NII segment reached 31.94 times subscription
• Total bids worth ₹6,067.41 crores received
• Applications reached 17,56,226 showing massive interest
• QIB portion at 0.37 times subscription
• Final day demonstrating tremendous investor confidence

Senores Pharmaceuticals IPO - Day 2 Subscription at 14.65 Times

Key Highlights:

• Overall subscription surged to 14.65 times
• Retail investors showed strong interest with 40.38 times subscription
• Non-institutional investors reached 25.74 times
• QIB portion improved to 0.36 times
• Market response indicating robust demand
• Small NII segment achieved 36.64 times subscription
• Large NII segment reached 20.70 times
• Day two witnessed accelerated momentum
• Subscription trend showing strong investor appetite

Senores Pharmaceuticals IPO - Day 1 Subscription at 1.94 Times

Key Highlights - Day 1:

• Overall subscription opened at 1.94 times
• Retail investors began strong with 7.90 times subscription
• Non-institutional investors started at 1.77 times
• QIB portion started at 0.01 times
• Opening day showed promising response
• Small NII segment reached 3.15 times subscription
• Large NII segment achieved 1.13 times
• Initial momentum indicating strong interest
• Market response suggesting high confidence

About Senores Pharmaceuticals Limited: 

Founded in December 2017, Senores Pharmaceuticals Limited has rapidly established itself as a specialized pharmaceutical manufacturer focusing on regulated markets including the US, Canada, and the UK. Their comprehensive product portfolio spans 55 products across key therapeutic areas, with particular strength in antibiotics and anti-fungal treatments.

Operating through three dedicated R&D facilities across India and the US, along with their manufacturing facility in Ahmedabad, Gujarat, the company has demonstrated impressive growth trajectory. Their financial performance has been particularly strong, achieving 457% revenue growth and 288% PAT increase between FY2023 and FY2024, highlighting their successful penetration of regulated markets and expansion into emerging markets across 43 countries.
 

Highlights of the Senores Pharmaceuticals IPO:

• IPO type: Book Built Issue
• IPO size: ₹582.11 crores
• Fresh Issue: ₹500.00 crores
• Offer for Sale: ₹82.11 crores
• Face value: ₹10 per share
• Price band: ₹372 to ₹391 per share
• Lot size: 38 shares
• Minimum investment for retail investors: ₹14,858
• Minimum investment for sNII: ₹2,08,012 (14 lots)
• Minimum investment for bNII: ₹10,10,344 (68 lots)
• Listing at: BSE, NSE
• IPO opens: December 20, 2024
• IPO closes: December 24, 2024
• Allotment date: December 26, 2024
• Refund initiation: December 27, 2024
• Credit of shares: December 27, 2024
• Listing date: December 30, 2024
• Lead Managers: Equirus Capital Private Limited, Ambit Private Limited, Nuvama Wealth Management Limited
• Registrar: Link Intime India Private Ltd

The strong first-day retail response and substantial anchor participation suggest market recognition of Senores Pharmaceuticals' potential in the growing pharmaceutical manufacturing sector, particularly in regulated markets.